“Plasma exosome-derived fragile site-associated tumor suppressor as a powerful prognostic predictor for patients with ovarian cancer” (2022) Biomolecules and Biomedicine, 22(3), pp. 453–459. doi:10.17305/bjbms.2021.6404.